Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

IntelGenx Corp. IGXT announced that it has resubmitted its new drug application (“NDA”) for Rizaport VersaFilm for the treatment of acute migraines to the FDA. The company received a Complete Response ...

IntelGenx (IGXT) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.01 per share a year ago. These figures are adjusted for ...

IntelGenx Technologies Corp. IGX IGXT reported its financial results late Thursday for the third quarter that ended September 30, 2022. Dr. Horst G. Zerbe, CEO of IntelGenx called the third quarter a ...

Intelgenx Technologies (IGXT) is scheduled to report earnings on May 14, 2025. The last reported earnings were for reported on May 15, 2024 for Q1.

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...

IntelGenx (IGXT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.03 per share a year ago. These figures are ...

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a ...

MONTREAL, July 19, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OTC: IGXT), a leading drug delivery company focused on the development and manufacturing of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.